Gül Kanyılmaz1, Berrin Benli Yavuz1, Meryem Aktan1, Mustafa Karaağaç2, Mehmet Uyar3, Sıddıka Fındık4. 1. Department of Radiation Oncology, Necmettin Erbakan University, Meram School of Medicine, Konya, Turkey. 2. Department of Clinical Oncology, Necmettin Erbakan University, Meram School of Medicine, Konya, Turkey. 3. Department of Public Health and Biostatistics, Necmettin Erbakan University, Meram School of Medicine, Konya, Turkey. 4. Department of Pathology, Necmettin Erbakan University, Meram School of Medicine, Konya, Turkey.
Abstract
OBJECTIVE: The clinical feature of breast cancer is very heterogeneous because of the variable prognostic factors impact its behaviour. The aim of study is to find the prognostic importance of Ki-67 and to analyse the correlation between Ki-67 index and the other conventional prognostic factors in breast cancer patients. MATERIALS AND METHODS: Between 2010 and 2017, patients with invasive ductal carcinoma who received radiotherapy after surgery were included in study. A single pathologist re-defined of all cases retrospectively. Ki-67 were established three categories based on Ki-67 levels: low (<10%), intermediate (10-25%) and high (>25%). RESULTS: A total of 258 patients were included. 46 of 258 (18%) patients were in low, 82 of 258 (32%) patients were in intermediate and 130 of 258 (50%) patients were in high Ki-67 group. There were no correlations between menopausal status, age, and Ki-67 level. Low-pT stages tended to have low Ki-67 expression (p=0.07). Low-pN stages correlated with low Ki-67 values (p=0.007). Patients with ECE (+) were prone to have higher Ki-67 values (p=0.02). The significant correlation was seen between Ki-67 and tumour grading (p=<0.0001). Patients with LVI (+) had higher Ki-67 expression (p=0.007). Luminal A tumours were correlated with low Ki-67 group (p=<0.0001). Ki-67 values had significant effect on DFS (p=0.03) but not OS (p=0.09). CONCLUSION: This study showed that high Ki-67 expression is associated with higher pT-stage, higher pN-stage, higher grade, ER/PR negativity, HER2/neu positivity, ECE and LVI positivity. The prognostic impact of Ki-67 was only demonstrated for DFS.
OBJECTIVE: The clinical feature of breast cancer is very heterogeneous because of the variable prognostic factors impact its behaviour. The aim of study is to find the prognostic importance of Ki-67 and to analyse the correlation between Ki-67 index and the other conventional prognostic factors in breast cancer patients. MATERIALS AND METHODS: Between 2010 and 2017, patients with invasive ductal carcinoma who received radiotherapy after surgery were included in study. A single pathologist re-defined of all cases retrospectively. Ki-67 were established three categories based on Ki-67 levels: low (<10%), intermediate (10-25%) and high (>25%). RESULTS: A total of 258 patients were included. 46 of 258 (18%) patients were in low, 82 of 258 (32%) patients were in intermediate and 130 of 258 (50%) patients were in high Ki-67 group. There were no correlations between menopausal status, age, and Ki-67 level. Low-pT stages tended to have low Ki-67 expression (p=0.07). Low-pN stages correlated with low Ki-67 values (p=0.007). Patients with ECE (+) were prone to have higher Ki-67 values (p=0.02). The significant correlation was seen between Ki-67 and tumour grading (p=<0.0001). Patients with LVI (+) had higher Ki-67 expression (p=0.007). Luminal A tumours were correlated with low Ki-67 group (p=<0.0001). Ki-67 values had significant effect on DFS (p=0.03) but not OS (p=0.09). CONCLUSION: This study showed that high Ki-67 expression is associated with higher pT-stage, higher pN-stage, higher grade, ER/PR negativity, HER2/neu positivity, ECE and LVI positivity. The prognostic impact of Ki-67 was only demonstrated for DFS.
Authors: A S Coates; E P Winer; A Goldhirsch; R D Gelber; M Gnant; M Piccart-Gebhart; B Thürlimann; H-J Senn Journal: Ann Oncol Date: 2015-05-04 Impact factor: 32.976
Authors: V Zenzola; M A Cabezas-Quintario; M Arguelles; E Pérez-Fernández; Y Izarzugaza; A Correa; J García-Foncillas Journal: Clin Transl Oncol Date: 2018-04-18 Impact factor: 3.405
Authors: T Tanei; A Shimomura; K Shimazu; T Nakayama; S J Kim; T Iwamoto; Y Tamaki; S Noguchi Journal: Eur J Surg Oncol Date: 2010-12-15 Impact factor: 4.424
Authors: R Colomer; I Aranda-López; J Albanell; T García-Caballero; E Ciruelos; M Á López-García; J Cortés; F Rojo; M Martín; J Palacios-Calvo Journal: Clin Transl Oncol Date: 2017-12-22 Impact factor: 3.405
Authors: Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes Journal: J Clin Oncol Date: 2013-10-07 Impact factor: 44.544
Authors: Mariko Asaoka; Santosh K Patnaik; Frank Zhang; Takashi Ishikawa; Kazuaki Takabe Journal: Breast Cancer Res Treat Date: 2020-04-13 Impact factor: 4.872
Authors: Okechinyere J Achilonu; Elvira Singh; Gideon Nimako; René M J C Eijkemans; Eustasius Musenge Journal: Biomed Res Int Date: 2022-01-20 Impact factor: 3.411
Authors: Radwa Sharaf; Meagan Montesion; Julia F Hopkins; Jiarong Song; Garrett M Frampton; Lee A Albacker Journal: Genome Med Date: 2022-02-26 Impact factor: 11.117